Hyloris Pharmaceuticals SaEURONEXT: HYL

Hyloris Pharmaceuticals Announces Strategic Partnership with Orion for its RTU Pantoprazole IV in European Markets

Jan 19, 2026 at 8:49 PM UTC · Issued by Hyloris Pharmaceuticals SA

19 Jan 2026 21:44 CET

Subscribe

Issuer

HYLORIS PHARMACEUTICALS SA

press-releasehylorisorionpantortueuropeen20260119.pdf

Source

HYLORIS

Provider

Euronext

Company Name

HYLORIS

ISIN

BE0974363955

Symbol

HYL

Market

Euronext

Earlier from Hyloris Pharmaceuticals Sa

Hyloris Pharmaceuticals: Licenses European and Turkish Rights to Next-Generation Wilson’s Disease Candidate from ArborMedDec 30, 2025
Hyloris Pharmaceuticals: Inside Information Hyloris Announces Partnership with Rosemont Pharmaceuticals for Atomoxetine Oral Solution in the U.S. ENGLISH VERSIONDec 29, 2025
Hyloris Pharmaceuticals: Receives Exclusive License Option for Innovative Topical Therapy for a Rare Genetic Skin DisorderDec 11, 2025
Hyloris Pharmaceuticals: Board of Directors appoints Stijn Van Rompay as CEONov 19, 2025

All Hyloris Pharmaceuticals Sa news releases